Recovery Pharmacogenomics
Variants in CYP2D6, CYP2C19, OPRM1 and DRD2 shape how members respond to addiction-medicine treatments - buprenorphine, naltrexone, methadone. Knowing a member's pharmacogenomic profile lets clinicians choose what's likely to work the first time.